Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. (Q43932350)

28 November 2017

title

Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP. (English)

1 reference

28 November 2017

1 reference

B Thayaparasingham

1

1 reference

28 November 2017

A Kunz

series ordinal

2

1 reference

28 November 2017

N Peters

series ordinal

3

1 reference

28 November 2017

D Kulms

series ordinal

4

1 reference

28 November 2017

language of work or name

English

0 references

publication date

3 November 2008

1 reference

28 November 2017

1 reference

28 November 2017

volume

28

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

345-362

1 reference

The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Role of nuclear factor-kappa B in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Selective expression of FLIP in malignant melanocytic skin lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Human cutaneous malignant melanoma as a model for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

An IAP-IAP complex inhibits apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

TRAIL signalling: decisions between life and death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Chemotherapy and targeted therapy combinations in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The promise of TRAIL--potential and risks of a novel anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF-kappaB regulation in the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Molecular events in melanoma development and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

TRAIL in cancer therapy: present and future challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF-kappaB signals induce the expression of c-FLIP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Controlling TRAIL-mediated caspase-3 activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

The proteasome is required for rapid initiation of death receptor-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF-kappaB activation in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Involvement of inhibitory nuclear factor-kappaB (NFkappaB)-independent NFkappaB activation in the gonadotropic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Identification and characterization of a new member of the TNF family that induces apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.397

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.397

1 reference

Dimensions Publication ID

28 November 2017

1004088823

0 references

1 reference